We found that PCLX-001 treated BL2, Ramos, BJAB, DOHH2, WSU-DLCL2, and SU-DHL-10 lymphoma cells all exhibit a more pronounced dose and time dependent decrease in Src and Lyn SFK protein levels in comparison to benign IM9 and VDS controls (Fig. 3a). The gene discussed is SRC; the disease is lymphoma.